Matthew B. Klein is Director of ClearPoint Neuro, Inc.. Currently has a direct ownership of 29,425 shares of CLPT, which is worth approximately $379,288. The most recent transaction as insider was on May 14, 2024, when has been sold 17,153 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 29.4K
0% 3M change
139.77% 12M change
Total Value Held $379,288

Matthew B. Klein Transaction History

Date Transaction Value Shares Traded Shares Held Form
May 14 2024
BUY
Exercise of conversion of derivative security
-
17,153 Added 36.83%
29,425 Common Stock
May 25 2022
BUY
Grant, award, or other acquisition
-
9,269 Added 43.03%
12,272 Common Stock
Jun 25 2021
BUY
Grant, award, or other acquisition
-
3,003 Added 50.0%
3,003 Common Stock

Also insider at

PTCT
PTC THERAPEUTICS, INC. Healthcare
MBK

Matthew B. Klein

Director
South Plainfield, NJ

Track Institutional and Insider Activities on CLPT

Follow ClearPoint Neuro, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CLPT shares.

Notify only if

Insider Trading

Get notified when an Clear Point Neuro, Inc. insider buys or sells CLPT shares.

Notify only if

News

Receive news related to ClearPoint Neuro, Inc.

Track Activities on CLPT